Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Celularity (CELU) EBITDA Margin (2020 - 2025)

Celularity (CELU) has disclosed EBITDA Margin for 6 consecutive years, with 436.66% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin fell 26347.0% to 436.66% in Q3 2025 year-over-year; TTM through Sep 2025 was 348.6%, a 27122.0% decrease, with the full-year FY2024 number at 106.78%, up 75462.0% from a year prior.
  • EBITDA Margin was 436.66% for Q3 2025 at Celularity, down from 427.6% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1266.58% in Q2 2022 to a low of 2479.56% in Q3 2023.
  • A 5-year average of 602.81% and a median of 307.89% in 2021 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: skyrocketed 421475bps in 2021, then tumbled -290776bps in 2023.
  • Celularity's EBITDA Margin stood at 307.89% in 2021, then surged by 290bps to 586.27% in 2022, then crashed by -90bps to 60.3% in 2023, then plummeted by -3305bps to 1932.56% in 2024, then soared by 77bps to 436.66% in 2025.
  • Per Business Quant, the three most recent readings for CELU's EBITDA Margin are 436.66% (Q3 2025), 427.6% (Q2 2025), and 172.84% (Q1 2025).